Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 9/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | CPA2 | P48052 | 1/20 | 0.49 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834113 | 0.88 | FKBP1A (0.59) | ACEFKBP1ACPA1CPA2CPA4 | |
| SCHEMBL5833963 | 0.85 | FKBP1A (0.69) | FKBP1A | |
| SCHEMBL5834096 | 0.85 | FKBP1A (0.64) | ACEFKBP1ACPA1CPA2CPA4 | |
| SCHEMBL5833607 | 0.85 | FKBP1A (0.67) | FKBP1A | |
| SCHEMBL5834244 | 0.82 | KLK7 (0.52) | ACEFKBP1A | |
| SCHEMBL5833889 | 0.82 | FKBP1A (0.74) | FKBP1A | |
| SCHEMBL5833871 | 0.80 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL7616199 | 0.80 | FKBP1A (0.71) | FKBP1A | |
| SCHEMBL5833863 | 0.79 | FKBP1A (0.54) | ACEFKBP1A | |
| SCHEMBL6367888 | 0.74 | ACE (0.66) | ACELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | ACE 837/4885FKBP1A 2/4885CPA1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.